Sutro Biopharma, Inc
Sutro Biopharma is a U.S.-based biopharmaceutical company that develops therapeutic biologics using its XpressCF® and XpressCF+® cell-free protein synthesis platforms. Its pipeline has included antibody-drug conjugates and other engineered biologic candidates for oncology and immunology applications, with research, development, and manufacturing activities centered in the United States.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaCell-free expression platforms used to design and manufacture engineered proteins and biologics.
Internal therapeutic programs including ADCs and other oncology-focused biologics.
Revenue from partnered research, development, and manufacturing agreements.
Asiakkaat
Sutro’s customers are primarily pharmaceutical and biotechnology partners that pay for research, development, manufacturing, and collaboration access to its platform and programs. The company also develops its own product candidates for future commercialization, so its end markets include oncology and other therapeutic areas rather than direct patient sales today.
Large pharma companies that fund research, milestones, and development work under collaboration agreements.
Smaller biotech companies that use Sutro’s platform or co-develop specific biologic candidates.
Oncology and immunology patients and providers that would use approved products if candidates reach market.
Strategia
Sutro’s strategy is to focus resources on its preclinical pipeline and platform capabilities while using collaborations to fund development and broaden technical validation. The company is also shifting to an external manufacturing model and reducing investment in deprioritized programs to concentrate on higher-priority biologic candidates.
The company’s value depends on moving internal candidates into clinical development and eventual partnering or commercialization.
Partner payments help finance development and provide external endorsement of the platform.
Using CMOs reduces fixed facility burden and aligns capacity with a development-stage business model.
Maantiede
Sutro is headquartered in the United States and conducts its core research, development, and manufacturing activities there. Its collaboration base includes global pharmaceutical partners, and the company notes that future growth may depend partly on operating in foreign markets, which would add regulatory and execution complexity.
Riskit
Sutro is an early-stage biopharmaceutical company with no approved products, so its business depends on successful development, regulatory approval, and eventual commercialization of product candidates. It also faces heavy competition from better-capitalized drug developers, funding dependence on collaborations and capital markets, and execution risk as it transitions manufacturing and prioritizes its pipeline.
- Clinical and regulatory failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Product candidates may not demonstrate safety, efficacy, or approvability in trials.
Kohdistuu - Funding and liquidity dependenceVaikutus: KorkeaTodennäköisyys: Korkea
The company needs additional financing to advance programs and may not obtain it on acceptable terms.
Kohdistuu - Competitive displacementVaikutus: KorkeaTodennäköisyys: Kohtalainen
Larger biopharma companies can outspend Sutro and develop competing ADCs or biologics.
Kohdistuu: TF-targeting and ITGB6-targeting ADCs
- Manufacturing and outsourcing executionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Moving to third-party CMOs can create supply, quality, and timing risks.
Kohdistuu: Platform reagents and product candidates
Kirjanpito
Harkinnanvaraiset erätRevenue from partner agreements depends on estimating performance obligations and milestone achievement.
Vaikutus: Can cause lumpy quarterly revenue and judgment-sensitive estimates
Workforce reductions and facility decommissioning require accruals and estimate updates.
Vaikutus: Affects operating expense comparability and cash outflows
Employee equity awards are a recurring non-cash cost for a development-stage biotech.
Vaikutus: Impacts reported losses and dilution analysis
Manufacturing and lab facilities can generate lease liabilities, right-of-use assets, and exit charges.
Vaikutus: Affects balance sheet leverage and restructuring expense
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Zura Bio Ltd
ZURA · Biological Products, (No Diagnostic Substances)
Zura Bio Ltd is a U.S.-based clinical-stage biopharmaceutical company focused on developing antibody-based therapies for immune-mediated diseases.
Estrella Immunopharma, Inc.
ESLAW · Biological Products, (No Diagnostic Substances)
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
Cue Biopharma, Inc.
CUE · Pharmaceutical Preparations
Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable precision immunotherapies designed to selectively modulate disease-relevant T cells.
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Päivitetty: 24.9.2026